Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?
Would you use MRD status to guide your decision making?
Answer from: Medical Oncologist at Academic Institution
Excellent question without a clear answer. While several RCTs have looked at post-induction maintenance among patients without planned transplantations, the British Myeloma XI trial is the biggest RCT (to my knowledge) to clearly look at lenalidomide vs observation in transplant-ineligible patients....
Comments
Medical Oncologist at University of Chicago Excellent points about ixazomib and for showcasing...
Excellent points about ixazomib and for showcasing...